Pavlos Msaouel
Overview
Explore the profile of Pavlos Msaouel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
2339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torrado C, Nassif Haddad E, Somaiah N, Msaouel P, Lazar A, Piha-Paul S
J Immunother Precis Oncol
. 2025 Mar;
8(2):113-120.
PMID: 40070529
Soft tissue sarcomas (STSs) are a group of rare cancers, among which nuclear protein in testis (NUT) sarcomas represent an ultra-rare subset driven by gene fusions. This article presents two...
2.
Moussa M, Kovalenko I, Crupi E, Proskuriakova E, Geng Y, Fallara G, et al.
Bladder Cancer
. 2025 Mar;
10(4):300-312.
PMID: 40035076
Background: Antiangiogenic therapy had been tested in urothelial cancer (UC) without reaching the clinic. Objective: We provide a systematic review and meta-analysis of trials to assess efficacy of immune checkpoint...
3.
Jiwani R, Pal K, Paolucci I, Odisio B, Brock K, Tannir N, et al.
Oncologist
. 2025 Feb;
30(2).
PMID: 39963829
Background: The objective of this study was to develop and validate a radiomics-based machine learning (ML) model to differentiate between renal medullary carcinoma (RMC) and clear cell renal carcinoma (ccRCC)....
4.
Moussa M, Khandelwal J, Wilson N, Malikayil K, Surasi D, Bathala T, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39939142
Background: Nivolumab plus ipilimumab (nivo/ipi) is a standard of care first-line (1 L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC), but its role in patients with metastatic,...
5.
Sherry A, Ludmir E, Msaouel P
Lancet
. 2025 Feb;
405(10476):380-381.
PMID: 39892905
No abstract available.
6.
Sherry A, Msaouel P, Lin T, Abi Jaoude J, Kouzy R, Beck E, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000322.
PMID: 39886131
Objective: Estimations of the treatment effect on overall survival (OS) may be influenced by post-progression therapies (PPTs). It is unclear how often OS analyses account for PPT effects. The purpose...
7.
Sherry A, Liu Y, Msaouel P, Lin T, Koong A, Lin C, et al.
medRxiv
. 2025 Jan;
PMID: 39867397
Background: Statistical significance currently defines superiority in phase III oncology trials. However, this practice is increasingly questioned. Here, we estimated the fragility of phase III oncology trials. Methods: Using Kaplan-Meier...
8.
Grimm S, Karki M, Blum K, Bertocchio J, He R, Tripathi D, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836407
Purpose: Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of the SMARCB1 tumor suppressor. It mainly affects young individuals of African descent with sickle cell...
9.
Gubbiotti M, McCutcheon I, Rao P, Genovese G, Wang L, Tarasov A, et al.
Acta Neuropathol Commun
. 2025 Jan;
13(1):12.
PMID: 39833894
Renal medullary carcinoma is a rare undifferentiated tumor of the kidney associated with sickle cell trait and characterized by INI1 (SMARCB1) loss. Although metastasis to lungs, lymph nodes, and bone...
10.
Moussa M, Tabet G, Siefker-Radtke A, Xiao L, Wilson N, Gao J, et al.
Cancer Med
. 2025 Jan;
14(2):e70594.
PMID: 39831734
Introduction: Small cell neuroendocrine carcinoma of the urinary tract (SCNEC-URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after...